Literature DB >> 26135467

[Update on therapy of chronic heart failure. Innovations and studies from last year].

Sebastian Ewen1, Y Linicus2, M Böhm2.   

Abstract

Chronic heart failure is one of the most common chronic diseases worldwide with increasing prevalence and incidence. Due to the high morbidity and mortality a standardized and evidence-based therapy is crucial. The present review article gives an overview about the innovations in 2014 based on the current guidelines of the European Society of Cardiology. First, improvements in established medication regimens regarding beta blockers and mineralocorticoid receptor antagonists as well as treatment options for heart rate reduction will be explained. Second, new pharmacological developments, such as angiotensin receptor neprilysin inhibition will be discussed. Finally, new insights into common comorbidities of patients with chronic heart failure, such as atrial fibrillation and hyperkalemia will be presented.

Entities:  

Keywords:  Acute and chronic heart failure; Bendopnea; Comorbidity; European Society of Cardiology guidelines; Pharmacological therapy

Mesh:

Substances:

Year:  2015        PMID: 26135467     DOI: 10.1007/s00059-015-4334-z

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  33 in total

1.  Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.

Authors:  Ali Vazir; Brian Claggett; Pardeep Jhund; Davide Castagno; Hicham Skali; Salim Yusuf; Karl Swedberg; Christopher B Granger; John J V McMurray; Marc A Pfeffer; Scott D Solomon
Journal:  Eur Heart J       Date:  2014-11-02       Impact factor: 29.983

2.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.

Authors:  Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

3.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

4.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

5.  Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.

Authors:  Orly Vardeny; Brian Claggett; Inder Anand; Patrick Rossignol; Akshay S Desai; Faiez Zannad; Bertram Pitt; Scott D Solomon
Journal:  Circ Heart Fail       Date:  2014-05-08       Impact factor: 8.790

6.  New-onset atrial fibrillation predicts heart failure progression.

Authors:  Ryan G Aleong; William H Sauer; Gordon Davis; Michael R Bristow
Journal:  Am J Med       Date:  2014-06-12       Impact factor: 4.965

7.  Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).

Authors:  Patrick Rossignol; Daniela Dobre; John J V McMurray; Karl Swedberg; Henry Krum; Dirk J van Veldhuisen; Harry Shi; Michael Messig; John Vincent; Nicolas Girerd; George Bakris; Bertram Pitt; Faiez Zannad
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

8.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.

Authors:  Dipak Kotecha; Jane Holmes; Henry Krum; Douglas G Altman; Luis Manzano; John G F Cleland; Gregory Y H Lip; Andrew J S Coats; Bert Andersson; Paulus Kirchhof; Thomas G von Lueder; Hans Wedel; Giuseppe Rosano; Marcelo C Shibata; Alan Rigby; Marcus D Flather
Journal:  Lancet       Date:  2014-09-02       Impact factor: 79.321

9.  Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database.

Authors:  Pierre Sabouret; Leyla Depret-Bixio; François-Emery Cotte; Pierre Marie; Nabil Bedira; Patrick Blin
Journal:  Clin Res Cardiol       Date:  2014-05-15       Impact factor: 5.460

10.  Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.

Authors:  Milton Packer; John J V McMurray; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael Zile; Karl Andersen; Juan Luis Arango; J Malcolm Arnold; Jan Bělohlávek; Michael Böhm; Sergey Boytsov; Lesley J Burgess; Walter Cabrera; Carlos Calvo; Chen-Huan Chen; Andrej Dukat; Yan Carlos Duarte; Andrejs Erglis; Michael Fu; Efrain Gomez; Angel Gonzàlez-Medina; Albert A Hagège; Jun Huang; Tzvetana Katova; Songsak Kiatchoosakun; Kee-Sik Kim; Ömer Kozan; Edmundo Bayram Llamas; Felipe Martinez; Bela Merkely; Iván Mendoza; Arend Mosterd; Marta Negrusz-Kawecka; Keijo Peuhkurinen; Felix J A Ramires; Jens Refsgaard; Arvo Rosenthal; Michele Senni; Antonio S Sibulo; José Silva-Cardoso; Iain B Squire; Randall C Starling; John R Teerlink; Johan Vanhaecke; Dragos Vinereanu; Raymond Ching-Chiew Wong
Journal:  Circulation       Date:  2014-11-17       Impact factor: 29.690

View more
  1 in total

1.  [Differences between German and Turkish-speaking participants in a chronic heart failure management program].

Authors:  N Ernstmann; U Karbach
Journal:  Herz       Date:  2016-06-22       Impact factor: 1.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.